ClinicalTrials.gg

Program

LTI-03

Also written as “Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)”.

Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by 2 companies.

Furthest: phase 2, since Apr 28, 20253 company-led studies, 1 open or runningNext primary completion: Sep 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Rein Therapeutics21 open or runningphase 2since Apr 28, 2025May 20, 2022Sep 30, 2027phase 2 · NCT06968845
Lung Therapeutics10 open or runningphase 1since Jan 12, 2020Jan 12, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 12, 2020First study: phase 1 study in Idiopathic Pulmonary FibrosisNew to Lung TherapeuticsLung Therapeutics · NCT04233814 · 71 enrolled · United Kingdom
  2. May 20, 2022Rein Therapeutics's first study: phase 1 study in Idiopathic Pulmonary FibrosisNew to Rein TherapeuticsRein Therapeutics · NCT05954988 · 24 enrolled · United States, Germany, United Kingdom
  3. Apr 28, 2025Phase 2 study in Idiopathic Pulmonary FibrosisRein Therapeutics · NCT06968845 · 120 planned · United States, Australia, Bulgaria and more

Ahead

  1. Sep 30, 2027Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisRein Therapeutics · NCT06968845

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06968845Idiopathic Pulmonary Fibrosis · United States, Australia, Bulgaria and more2RecruitingRein TherapeuticsSep 30, 2027120
NCT05954988Idiopathic Pulmonary Fibrosis · United States, Germany, United Kingdom1CompletedRein TherapeuticsSep 25, 202424
NCT04233814Idiopathic Pulmonary Fibrosis · United Kingdom1CompletedLung TherapeuticsDec 23, 202171

How it is read

Names in the registry

  • “LTI-03”, 2 entries
  • “Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
LTI-03 (Rein Therapeutics): development program | ClinicalTrials.gg